The Experts below are selected from a list of 3297 Experts worldwide ranked by ideXlab platform
Ospina Ujueta, Lina María - One of the best experts on this subject based on the ideXlab platform.
-
Olé - sistema de empaque para paella de consumo individual
'Universidad de Los Andes - Facultad de Arquitectura y Diseno', 2017Co-Authors: Azula Herrera, Carlos Alberto, Cifuentes Gamboa, Diana Josefa, Ospina Ujueta, Lina MaríaAbstract:Sistema de empaque individual para consumo de paella a domicilio y/o take away que genere una experiencia de consumo similar a la que se tendría en el restaurante, buscando que sea ambientalmente sostenible, conserve las propiedades organolépticas y vaya acorde a la cultura gastronómica española en su parte formal-estética.Individual packaging system for consumption of paella delivery and take away, that generates a experience similar to what would be at the restaurant, being a product environmentally sustainable, preserve the organoleptic properties and go according to the Spaniard gastronomic culture formal - esthetic.Diseñador (a) IndustrialPregrad
-
Olé - sistema de empaque para paella de consumo individual
Diseño Industrial, 2017Co-Authors: Azula Herrera, Carlos Alberto, Cifuentes Gamboa, Diana Josefa, Ospina Ujueta, Lina MaríaAbstract:Sistema de empaque individual para consumo de paella a domicilio y/o take away que genere una experiencia de consumo similar a la que se tendría en el restaurante, buscando que sea ambientalmente sostenible, conserve las propiedades organolépticas y vaya acorde a la cultura gastronómica española en su parte formal-estética.Individual packaging system for consumption of paella delivery and take away, that generates a experience similar to what would be at the restaurant, being a product environmentally sustainable, preserve the organoleptic properties and go according to the Spaniard gastronomic culture formal - esthetic
C. De Mendoza - One of the best experts on this subject based on the ideXlab platform.
-
HTLV-1 infection in solid organ transplant donors and recipients in Spain
'Springer Science and Business Media LLC', 2019Co-Authors: C. De Mendoza, Roc Lourdes, Benito Rafael, Reina Gabriel, Ramos, José M., Gómez Cesar, Spanish Htlv NetworkAbstract:Adult T-cell leukaemia; HTLV-1; ImmunosuppressionLeucemia de células T adultas; HTLV-1; InmunosupresiónLeucèmia de cèl·lules T adultes; HTLV-1; ImmunosupressióBackground: HTLV-1 infection is a neglected disease, despite infecting 10–15 million people worldwide and severe illnesses develop in 10% of carriers lifelong. Acknowledging a greater risk for developing HTLV-1 associated illnesses due to immunosuppression, screening is being widely considered in the transplantation setting. Herein, we report the experience with universal HTLV testing of donors and recipients of solid organ transplants in a survey conducted in Spain. Methods: All hospitals belonging to the Spanish HTLV network were invited to participate in the study. Briefly, HTLV antibody screening was performed retrospectively in all specimens collected from solid organ donors and recipients attended since the year 2008. Results: A total of 5751 individuals were tested for HTLV antibodies at 8 sites. Donors represented 2312 (42.2%), of whom 17 (0.3%) were living kidney donors. The remaining 3439 (59.8%) were recipients. Spaniards represented nearly 80%. Overall, 9 individuals (0.16%) were initially reactive for HTLV antibodies. Six were donors and 3 were recipients. Using confirmatory tests, HTLV-1 could be confirmed in only two donors, one Spaniard and another from Colombia. Both kidneys of the Spaniard were inadvertently transplanted. Subacute myelopathy developed within 1 year in one recipient. The second recipient seroconverted for HTLV-1 but the kidney had to be removed soon due to rejection. Immunosuppression was stopped and 3 years later the patient remains in dialysis but otherwise asymptomatic. Conclusion: The rate of HTLV-1 is low but not negligible in donors/recipients of solid organ transplants in Spain. Universal HTLV screening should be recommended in all donor and recipients of solid organ transplantation in Spain. Evidence is overwhelming for very high virus transmission and increased risk along with the rapid development of subacute myelopathy
-
HTLV-1 infection in solid organ transplant donors and recipients in Spain
'Springer Science and Business Media LLC', 2019Co-Authors: C. De Mendoza, Roc Lourdes, Benito Rafael, Reina Gabriel, Ramos, José M., Gómez Cesar, Aguilera Antonio, Rodríguez-iglesias Manuel, García-costa Juan, Fernández-alonso MiriamAbstract:Consortia on behalf of the Spanish HTLV Network: C. Rodríguez, M. Vera, J. del Romero, G. Marcaida, M. D. Ocete, E. Caballero, I. Molina, A. Aguilera, J. J. Rodríguez-Calviño, D. Navarro, C. Rivero, M. D. Vilariño, R. Benito, S. Algarate, J. Gil, R. Ortiz de Lejarazu, S. Rojo, J. M. Eirós, A. San Miguel, C. Manzardo, J. M. Miró, J. García, I. Paz, E. Poveda, E. Calderón, D. Escudero, M. Trigo, J. Diz, M. García-Campello, M. Rodríguez Iglesias, A. Hernández Betancor, A. M. Martín, J. M. Ramos, A. Gimeno, F. Gutiérrez, J. C. Rodríguez, V. Sánchez, C. Gómez Hernando, G. Cilla, E. Pérez Trallero, J. López Aldeguer, L. Fernández Pereira, J. Niubó, M. Hernández, A. M. López Lirola, J. L. Gómez Sirvent, L. Force, C. Cifuentes, S. Pérez, L. Morano, C. Raya, A. González Praetorius, J. L. Pérez, M. Peñaranda, S. Hernáez Crespo, J. M. Montejo, L. Roc, A. Martínez Sapiña, I. Viciana, T. Cabezas, A. Lozano, J. M. Fernández, I. García-Bermejo, G. Gaspar, R. García, M. Górgolas, C. Vegas, J. Blas, P. Miralles, M. Valeiro, T. Aldamiz, N. Margall, C. Guardia, E. do Pico, I. Polo, A. Aguinaga, C. Ezpeleta, S. Sauleda, M. Pirón, R. González, L. Barea, A. Jiménez, L. Blanco, A. Suárez, I. Rodríguez Avial, A. Pérez Rivilla, P. Parra, M. Fernández, M. Fernández Alonso, A. Treviño, S. Requena, L. Benítez Gutiérrez, V. Cuervas Mons, C. de Mendoza, P. Barreiro, V. Soriano, O. Corral & F. Gómez-Gallego[Background]: HTLV-1 infection is a neglected disease, despite infecting 10–15 million people worldwide and severe illnesses develop in 10% of carriers lifelong. Acknowledging a greater risk for developing HTLV-1 associated illnesses due to immunosuppression, screening is being widely considered in the transplantation setting. Herein, we report the experience with universal HTLV testing of donors and recipients of solid organ transplants in a survey conducted in Spain.[Methods]: All hospitals belonging to the Spanish HTLV network were invited to participate in the study. Briefly, HTLV antibody screening was performed retrospectively in all specimens collected from solid organ donors and recipients attended since the year 2008.[Results]: A total of 5751 individuals were tested for HTLV antibodies at 8 sites. Donors represented 2312 (42.2%), of whom 17 (0.3%) were living kidney donors. The remaining 3439 (59.8%) were recipients. Spaniards represented nearly 80%. Overall, 9 individuals (0.16%) were initially reactive for HTLV antibodies. Six were donors and 3 were recipients. Using confirmatory tests, HTLV-1 could be confirmed in only two donors, one Spaniard and another from Colombia. Both kidneys of the Spaniard were inadvertently transplanted. Subacute myelopathy developed within 1 year in one recipient. The second recipient seroconverted for HTLV-1 but the kidney had to be removed soon due to rejection. Immunosuppression was stopped and 3 years later the patient remains in dialysis but otherwise asymptomatic.[Conclusion]: The rate of HTLV-1 is low but not negligible in donors/recipients of solid organ transplants in Spain. Universal HTLV screening should be recommended in all donor and recipients of solid organ transplantation in Spain. Evidence is overwhelming for very high virus transmission and increased risk along with the rapid development of subacute myelopathy.Peer reviewe
-
Clinical Presentation of Individuals With Human T-Cell Leukemia Virus Type-1 Infection in Spain
2019Co-Authors: C. De Mendoza, Roc Lourdes, Benito Rafael, González Rocío, Pirón María, Jiménez Ana, Caballero Estrella, Ramos, José Manuel, Soriano VicenteAbstract:Background: although only 8%-10% of persons infected with human T-cell leukemia virus type 1 (HTLV-1) may develop virus-associated diseases lifelong, misdiagnosis of asymptomatic infected carriers frequently leads to late diagnoses. Methods: a nationwide HTLV-1 register was created in Spain in 1989. A total of 351 infected persons had been reported by the end of 2017. We examined all new HTLV-1 diagnoses during the last decade and compared their clinical presentation. Results: a total of 247 individuals with HTLV-1 infection had been reported in Spain since year 2008. The incidence has remained stable with 20-25 new diagnoses yearly. Women represented 62%. Only 12% were native Spaniards, most of whom were foreigners from Latin America (72.5%). Up to 57 (23%) individuals presented clinically with HTLV-1-associated conditions, including subacute myelopathy (n = 24; 42.1%), T-cell lymphoma (n = 19; 33.3%), or Strongyloides stercoralis infestation (n = 8; 14%). Human T-cell leukemia virus type 1 diagnosis had been made either at blood banks (n = 109; 44%) or at clinics (n = 138; 56%). It is interesting to note that Spaniards and especially Africans were overrepresented among patients presenting with HTLV-1-associated illnesses, suggesting that misdiagnosis and late presentation are more frequent in these populations compared to Latin Americans. Conclusions: given that 23% of new HTLV-1 diagnoses in Spain are symptomatic, underdiagnosis must be common. Although screening in blood banks mostly identifies asymptomatic Latin American carriers, a disproportionately high number of Spaniards and Africans are unveiled too late, that is, they already suffer from classic HTLV-1 illnesses
-
Rapid subacute myelopathy following kidney transplantation from HTLV-1 donors: role of immunosuppresors and failure of antiretrovirals
'SAGE Publications', 2019Co-Authors: Roc Lourdes, C. De Mendoza, Reina Gabriel, Soriano Vicente, Fernández-alonso Miriam, Rodriguez C., Corral, Octavio Jorge, Gómez-gallego FelixAbstract:Two kidney transplant recipients from a single donor became infected with HTLV-1 (human T-lymphotropic virus type 1) in Spain. One developed myelopathy 8 months following surgery despite early prescription of antiretroviral therapy. The allograft was removed from the second recipient at month 8 due to rejection and immunosuppressors discontinued. To date, 3 years later, this patient remains infected but asymptomatic. HTLV-1 infection was recognized retrospectively in the donor, a native Spaniard who had sex partners from endemic regions. Our findings call for a reappraisal of screening policies on donor–recipient organ transplantation. Based on the high risk of disease development and the large flux of persons from HTLV-1 endemic regions, pre-transplant HTLV-1 testing should be mandatory in Spain
-
Prevalence and incidence of hepatitis delta in patients with chronic hepatitis B in Spain
European Journal of Gastroenterology & Hepatology, 2019Co-Authors: Aguilera Antonio, C. De Mendoza, Trastoy Rocío, Rodríguez-calviño Javier, Manso Tamara, Soriano VicenteAbstract:Background Hepatitis delta virus (HDV) is a defective agent that only replicates in the presence of the hepatitis B virus. Accordingly, HDV acquisition may occur as superinfection of HBsAg+ carriers or following acute dual HDV and hepatitis B virus exposure. Herein, we examined the global and incident rates of HDV infections in Spain. Patients and methods The presence of anti-HDV antibody and new HDV superinfections was examined in all HBsAg+ patients who attended one large tertiary outclinic in Spain since year 2000. Anti-HDV antibodies were tested repeatedly every 5 years in those previously negative. Results During a median follow-up of 12 years, 478 individuals were diagnosed as HBsAg+. Overall, 64.4% were male, median age was 55 years, 88.1% were native Spaniards, 6.5% were coinfected with HIV, and 7.3% were reactive for hepatitis C virus (HCV) antibodies. A total of 19 (4%) patients had anti-HDV antibody at first diagnosis. There were no further HDV seroconversions. Most anti-HDV + patients were male (n = 12), former injection drug users (n= 13), and native Spaniards (n= 16). Coinfection with HIV was found in six, and 12 had HCV antibodies. Interestingly, three of seven women with delta hepatitis were foreigners (Asian or African), denied injection drug use, were younger than 40 years old, and negative for both HCV and HIV. Conclusion The prevalence of chronic hepatitis delta is currently very low (< 5%) among chronic HBsAg+ carriers in Spain, with lower rates in recent years. Moreover, new incident HDV infections were not seen in 478 chronic hepatitis B carriers since year 2000, following drastic declines in injection drug use
Azula Herrera, Carlos Alberto - One of the best experts on this subject based on the ideXlab platform.
-
Olé - sistema de empaque para paella de consumo individual
'Universidad de Los Andes - Facultad de Arquitectura y Diseno', 2017Co-Authors: Azula Herrera, Carlos Alberto, Cifuentes Gamboa, Diana Josefa, Ospina Ujueta, Lina MaríaAbstract:Sistema de empaque individual para consumo de paella a domicilio y/o take away que genere una experiencia de consumo similar a la que se tendría en el restaurante, buscando que sea ambientalmente sostenible, conserve las propiedades organolépticas y vaya acorde a la cultura gastronómica española en su parte formal-estética.Individual packaging system for consumption of paella delivery and take away, that generates a experience similar to what would be at the restaurant, being a product environmentally sustainable, preserve the organoleptic properties and go according to the Spaniard gastronomic culture formal - esthetic.Diseñador (a) IndustrialPregrad
-
Olé - sistema de empaque para paella de consumo individual
Diseño Industrial, 2017Co-Authors: Azula Herrera, Carlos Alberto, Cifuentes Gamboa, Diana Josefa, Ospina Ujueta, Lina MaríaAbstract:Sistema de empaque individual para consumo de paella a domicilio y/o take away que genere una experiencia de consumo similar a la que se tendría en el restaurante, buscando que sea ambientalmente sostenible, conserve las propiedades organolépticas y vaya acorde a la cultura gastronómica española en su parte formal-estética.Individual packaging system for consumption of paella delivery and take away, that generates a experience similar to what would be at the restaurant, being a product environmentally sustainable, preserve the organoleptic properties and go according to the Spaniard gastronomic culture formal - esthetic
Soriano Vicente - One of the best experts on this subject based on the ideXlab platform.
-
Overt and occult hepatitis B among immigrants and native blood donors in Madrid, Spain
'SAGE Publications', 2021Co-Authors: González Rocío, Barea Luisa, Arruga Ana, Richart Alberto, Soriano VicenteAbstract:Background: The risk of transfusion-transmitted viral infections is very low in developed countries. Recent massive migration flows from highly hepatitis B virus (HBV), hepatitis C virus (HCV) and/or HIV endemic regions to Europe may have changed this scenario. Methods: During 2017 and 2018, a total of 491,753 blood donations (291,762 donors) were evaluated at the Madrid Regional Transfusion Center. All were tested for hepatitis B surface antigen (HBsAg), anti-HCV and anti-HIV, as well as for HBV-DNA, HCV-RNA and HIV-RNA. Results: Overall, 35 donors were positive for HIV-RNA and 26 for HCV-RNA. HBV markers were found in 111 (0.022%) donors, split out into three categories: HBsAg+ (n = 93; 0.019%), occult B infection (OBI) (n = 17; 0.003%), and acute HBV window period (n = 1; 0.0002%). All 17 OBI donors were positive for anti-HBc and confirmed as viremic in repeated testing. Viral load amounts were uniformly below 100 IU/mL. Ten OBI donors were repeated donors and look-back studies could be completed for eight of them. Fortunately, none of all prior recipients experienced transfusion transmitted hepatitis B. Compared with HBsAg+ donors, OBI donors were more frequently native Spaniards (76% versus 40%) and older (median age 52 versus 42 years old). Conclusion: Active HBV infection is currently found in 0.022% of blood donations (0.038% of donors) in Madrid. This rate is 3-fold greater than for HIV and/or HCV. On the other hand, HBsAg+ donors are 3-fold more frequent than OBI donors and more often immigrants than native Spaniards. No transfusion-transmitted HBV infections were identified during the study period, including retrospective checking of former recipients of OBI donors
-
Clinical Presentation of Individuals With Human T-Cell Leukemia Virus Type-1 Infection in Spain
2019Co-Authors: C. De Mendoza, Roc Lourdes, Benito Rafael, González Rocío, Pirón María, Jiménez Ana, Caballero Estrella, Ramos, José Manuel, Soriano VicenteAbstract:Background: although only 8%-10% of persons infected with human T-cell leukemia virus type 1 (HTLV-1) may develop virus-associated diseases lifelong, misdiagnosis of asymptomatic infected carriers frequently leads to late diagnoses. Methods: a nationwide HTLV-1 register was created in Spain in 1989. A total of 351 infected persons had been reported by the end of 2017. We examined all new HTLV-1 diagnoses during the last decade and compared their clinical presentation. Results: a total of 247 individuals with HTLV-1 infection had been reported in Spain since year 2008. The incidence has remained stable with 20-25 new diagnoses yearly. Women represented 62%. Only 12% were native Spaniards, most of whom were foreigners from Latin America (72.5%). Up to 57 (23%) individuals presented clinically with HTLV-1-associated conditions, including subacute myelopathy (n = 24; 42.1%), T-cell lymphoma (n = 19; 33.3%), or Strongyloides stercoralis infestation (n = 8; 14%). Human T-cell leukemia virus type 1 diagnosis had been made either at blood banks (n = 109; 44%) or at clinics (n = 138; 56%). It is interesting to note that Spaniards and especially Africans were overrepresented among patients presenting with HTLV-1-associated illnesses, suggesting that misdiagnosis and late presentation are more frequent in these populations compared to Latin Americans. Conclusions: given that 23% of new HTLV-1 diagnoses in Spain are symptomatic, underdiagnosis must be common. Although screening in blood banks mostly identifies asymptomatic Latin American carriers, a disproportionately high number of Spaniards and Africans are unveiled too late, that is, they already suffer from classic HTLV-1 illnesses
-
Rapid subacute myelopathy following kidney transplantation from HTLV-1 donors: role of immunosuppresors and failure of antiretrovirals
'SAGE Publications', 2019Co-Authors: Roc Lourdes, C. De Mendoza, Reina Gabriel, Soriano Vicente, Fernández-alonso Miriam, Rodriguez C., Corral, Octavio Jorge, Gómez-gallego FelixAbstract:Two kidney transplant recipients from a single donor became infected with HTLV-1 (human T-lymphotropic virus type 1) in Spain. One developed myelopathy 8 months following surgery despite early prescription of antiretroviral therapy. The allograft was removed from the second recipient at month 8 due to rejection and immunosuppressors discontinued. To date, 3 years later, this patient remains infected but asymptomatic. HTLV-1 infection was recognized retrospectively in the donor, a native Spaniard who had sex partners from endemic regions. Our findings call for a reappraisal of screening policies on donor–recipient organ transplantation. Based on the high risk of disease development and the large flux of persons from HTLV-1 endemic regions, pre-transplant HTLV-1 testing should be mandatory in Spain
-
Prevalence and incidence of hepatitis delta in patients with chronic hepatitis B in Spain
European Journal of Gastroenterology & Hepatology, 2019Co-Authors: Aguilera Antonio, C. De Mendoza, Trastoy Rocío, Rodríguez-calviño Javier, Manso Tamara, Soriano VicenteAbstract:Background Hepatitis delta virus (HDV) is a defective agent that only replicates in the presence of the hepatitis B virus. Accordingly, HDV acquisition may occur as superinfection of HBsAg+ carriers or following acute dual HDV and hepatitis B virus exposure. Herein, we examined the global and incident rates of HDV infections in Spain. Patients and methods The presence of anti-HDV antibody and new HDV superinfections was examined in all HBsAg+ patients who attended one large tertiary outclinic in Spain since year 2000. Anti-HDV antibodies were tested repeatedly every 5 years in those previously negative. Results During a median follow-up of 12 years, 478 individuals were diagnosed as HBsAg+. Overall, 64.4% were male, median age was 55 years, 88.1% were native Spaniards, 6.5% were coinfected with HIV, and 7.3% were reactive for hepatitis C virus (HCV) antibodies. A total of 19 (4%) patients had anti-HDV antibody at first diagnosis. There were no further HDV seroconversions. Most anti-HDV + patients were male (n = 12), former injection drug users (n= 13), and native Spaniards (n= 16). Coinfection with HIV was found in six, and 12 had HCV antibodies. Interestingly, three of seven women with delta hepatitis were foreigners (Asian or African), denied injection drug use, were younger than 40 years old, and negative for both HCV and HIV. Conclusion The prevalence of chronic hepatitis delta is currently very low (< 5%) among chronic HBsAg+ carriers in Spain, with lower rates in recent years. Moreover, new incident HDV infections were not seen in 478 chronic hepatitis B carriers since year 2000, following drastic declines in injection drug use
Adrian Llerena - One of the best experts on this subject based on the ideXlab platform.
-
cyp2c9 allele frequency differences between populations of mexican mestizo mexican tepehuano and Spaniards
Pharmacogenomics Journal, 2011Co-Authors: Pedro Dorado, M G Sosamacias, E Penaslledo, R E Alanisbanuelos, Mali Wong, Julio Licinio, I Laresasseff, Adrian LlerenaAbstract:Earlier we had found that the CYP2C9*2 allelic frequency was lower in Mexican-Americans living in California than in Spaniards (SP). This was assumed to be related to the low CYP2C9*2 and *3 allele frequencies in Orientals. This study was therefore aimed at analyzing whether there were also differences in CYP2C9 allele frequencies between Mexican-Tepehuanos (MT) and Mexican-Mestizos (MM) living in northwestern Mexico and SP. The CYP2C9*2 frequency was expected to be lower in the indigenous MT than in the two other groups, and lower in MM than in SP as in our earlier study. CYP2C9 genotypes and allele frequencies of two populations of healthy volunteers, MT (n=99) and MM (n=102), were compared with a population of SP (n=327). The data were also compared with our previously published population of Mestizo-Mexican-Americans (MA). The CYP2C9 genotypes among the studied populations were in equilibrium. The frequencies of CYP2C9*2 were 0.01, 0.07, 0.08, and 0.16 for MT, MM, MA, and SP subjects, respectively. In agreement with our hypothesis, CYP2C9*2 was significantly lower in the Mexican populations than in the SP (P<0.05), and among Mexicans in the MT than in the MM and MA groups (P<0.05), which presented similar frequencies. Moreover, the frequency of CYP2C9*3 was found to be lower (P<0.05) in MM (0.015) and MT (0.015) than in MA (0.06) and SP (0.08). Finally, the CYP2C9*6 allele was present just in one MM subject, and CYP2C9*4 and *5 were not found in the studied populations. Therefore, these findings add further evidence about CYP2C9 genetic diversity within Hispanic populations with regard to their ancestry. Considering that CYP2C9*2 and CYP2C9*3 alleles have altered catalytic activities relative to CYP2C9*1, the present data suggest the need for pharmacogenetic studies to optimize drug dosages in different populations.